Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

5.21

Today's Change

-0.01 (0.19%)

Day's Change

5.11 - 5.29

Trading Volume

173,728

Overview

Market Cap

1 Billion

Shares Outstanding

271 Million

Avg Volume

1,178,668

Avg Price (50 Days)

3.82

Avg Price (200 Days)

2.36

PE Ratio

-43.42

EPS

-0.12

Earnings Announcement

21-Aug-2024

Previous Close

5.22

Open

5.23

Day's Range

5.11 - 5.29

Year Range

0.675 - 5.67

Trading Volume

173,728

Price Change Highlight

1 Day Change

-0.19%

5 Day Change

0.39%

1 Month Change

32.57%

3 Month Change

97.35%

6 Month Change

215.76%

Ytd Change

148.10%

1 Year Change

561.55%

3 Year Change

247.33%

5 Year Change

247.33%

10 Year Change

247.33%

Max Change

247.33%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment